Valganciclovir Hydrochloride



Valganciclovir Hydrochloride





(val gan sigh’ kloe veer)

ValcyteDNC

PREGNANCY CATEGORY C


Drug Class

Antiviral


Therapeutic Actions

Antiviral activity; inhibits viral DNA replication in cytomegalovirus (CMV).


Indications



  • Treatment of CMV retinitis in patients with AIDS



  • Prevention of CMV infection in high-risk kidney-pancreas, kidney, and heart transplant patients


  • Prevention of CMV infection in pediatric patients with kidney or heart transplant at high risk for CMV infection



Contraindications and Cautions



  • Contraindicated with hypersensitivity to valganciclovir, ganciclovir, or acyclovir; lactation; liver transplant patients; ANC less 500 cells/mm3.


  • Use cautiously in the elderly; with cytopenia, history of cytopenic reactions, impaired renal function, bone marrow suppression, hemodialysis, pregnancy.


Available Forms

TabletsDNC—450 mg; oral solution—50 mg/mL


Dosages

Adults

900 mg PO bid for 21 days; maintenance, 900 mg PO daily.



  • Prevention of CMV: 900 mg PO daily initiated within 10 days of transplantation and continued for 100 days after transplantation

Pediatric patients 4 mo–16 yr

Dose in mg = 7 × BSA × CrCl PO. Maximum dose, 900 mg/day initiated within 10 days of transplantation and continued for 100 days after transplantation. May use oral solution or tablets.

Patients with renal impairment

Do not administer to patients on hemodialysis. For patients with renal impairment, see the following table:































CrCl (mL/min) Initial Dose Maintenance Dose
60 or more 900 mg PO bid 900 mg/day PO
40–59 450 mg PO bid 450 mg/day PO
25–39 450 mg PO daily 450 mg PO every other day
10–24 450 mg PO every 2 days 450 mg PO twice weekly
Less than 10 Not recommended  

Tags:
Jul 21, 2016 | Posted by in NURSING | Comments Off on Valganciclovir Hydrochloride

Full access? Get Clinical Tree
Get Clinical Tree app for offline access